Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026 HUTCHMED (China) Limited announced that AstraZeneca has submitted...
WILMINGTON, Del. — September 25, 2026 AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted and...
Cambridge, United Kingdom, September 23, 2026 AstraZeneca has announced that Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has received European Commission...
TOKYO — September 18, 2026 Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products...
Osaka, Japan & Cambridge, Massachusetts, U.S., September 14, 2026 Takeda has announced that the U.S. Food and Drug Administration...
Seoul, South Korea, September 14, 2026 AstraZeneca and Daiichi Sankyo announced positive results from the Phase III DESTINY-Lung04 trial,...
Wilmington, Delaware, U.S., September 14, 2026 AstraZeneca announced updated results from the Phase III ADAURA trial, showing sustained long-term...
Thousand Oaks, California, USA, September 8, 2026 Amgen and AstraZeneca have announced positive results from the Phase 3 DeLLphi-305...
Palo Alto, California — September 4, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has...
